Regenacy Pharmaceuticals partners with CMTA to advance ricolinostat for treating hereditary neuropathy

Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association (CMTA), a registered non-profit organization serving the hereditary neuropathy patient community, to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth (CMT) disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models. In addition, the company announced the appointment of David Herrmann, M.B.B.Ch., to its Scientific Advisory Board. Dr. Herrmann is Chief of the Neuromuscular Division & Director of the Peripheral Neuropathy Clinics and Cutaneous Innervation Laboratory in the Department of Neurology at the University of Rochester, and a member of the STAR (Strategy to Accelerate Research) advisory board for the CMTA.

"We are thrilled to have such a substantial collaboration to broaden our programs for ricolinostat into inherited forms of neuropathy where there is a tremendous unmet need," said Matt Jarpe, Ph.D., Vice President of R&D of Regenacy Pharmaceuticals. "This alliance with the Charcot-Marie-Tooth Association will enable us to expand our understanding of the role of HDAC6 in neuropathic diseases and lead us closer to initiating clinical trials in CMT disease."

CMT disease is a progressive and degenerative nerve disease that usually appears in adolescence or early adulthood. Symptoms can include muscle weakness, decreased muscle size, foot-drop, foot bone abnormalities, fatigue, balance problems, neuropathic and/or musculoskeletal pain, loss of feeling in the hands and feet and loss of coordination in the limbs. There are no FDA approved treatments to stop or reverse the loss of nerve function in CMT. Based on the terms of the collaboration, Regenacy has an opportunity to expand on the groundbreaking work of Dr. Ludo van den Bosch at University of Leuven and Dr. Andrew Grierson at University of Sheffield to show the role of HDAC6 in several forms of CMT Type 2. The collaboration will focus on evaluating the efficacy of ricolinostat in animal models of CMT to support initiation of clinical trials. This relationship is taking advantage of the extensive suite of expert preclinical testing capabilities the CMTA has assembled and makes available to groups such as Regenacy that want to evaluate therapeutic potential in a CMT disorder.

"In parallel to announcing our collaboration with CMTA, we are pleased to welcome Dr. David Herrmann to our Scientific Advisory Board," added Dr. Jarpe. "Dr. Herrmann brings to Regenacy relevant and valuable experience in clinical outcome measures in peripheral neuropathies, particularly CMT disease. We are looking forward to his contributions and proven strategic expertise as we continue to develop ricolinostat for the treatment of CMT."

Dr. Herrmann is currently Professor of Neurology, Pathology and Laboratory Medicine at the University of Rochester. He established one of the first cutaneous innervation laboratories in the United States at University of Rochester for diagnosis of small fiber neuropathy. In addition to his role on the STAR advisory board for the CMTA, Dr. Herrmann is a member of the Inherited Neuropathies Consortium. He is currently Principal Investigator in Rochester for the NIH sponsored Inherited Neuropathy Consortium Rare Disease Clinical Research Center. Dr. Herrmann received his medical degree from The University of Witwatersrand Medical School.

"I am personally passionate about inherited neuropathies for which there is an urgency to develop treatments," said Dr. Herrmann. "Current treatment options for Charcot-Marie-Tooth disease, and related disorders, are very limited so each potential new therapy can make a critical difference for patients in need. I am excited to collaborate with the highly regarded Regenacy team, who are leaders in the field and are committed to bringing forward new treatment options in various types of peripheral neuropathy."



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome